Evidence map›Paper›PMID 36256607›Full record

ArticlePLoS medicine2022

Association of sleep duration at age 50, 60, and 70 years with risk of multimorbidity in the UK: 25-year follow-up of the Whitehall II cohort study.

Séverine Sabia, Aline Dugravot, Damien Léger, Céline Ben Hassen, Mika Kivimaki, Archana Singh-Manoux

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Influence of an AQP4 haplotype and sleep duration on early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Séverine SabiaUniversité Paris Cité, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France.ORCID 0000-0003-3109-9720
Aline DugravotUniversité Paris Cité, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France.ORCID 0000-0002-4546-0970
Damien LégerUniversité Paris Cité, EA 7330 VIFASOM (Vigilance Fatigue Sommeil et Santé Publique), Paris, France.ORCID 0000-0003-1168-480X
Céline Ben HassenUniversité Paris Cité, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France.ORCID 0000-0001-7884-2986
Mika KivimakiDepartment of Epidemiology and Public Health, University College London, London, United Kingdom.ORCID 0000-0002-4699-5627
Archana Singh-ManouxUniversité Paris Cité, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France.ORCID 0000-0002-1244-5037
Inserm · FRUniversité Paris Cité · FRUniversity of Helsinki · FI

Funding

Education, socioeconomic status and Aging: transitions from multimorbidity to functional limitations and mortalityR01AG056477 · NIA · UNIVERSITY COLLEGE LONDON · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2018 to 2022
$2.8M
Role of mid- and late-life risk factors in social inequalities in Alzheimer's Disease and Related DementiasRF1AG062553 · NIA · INSERM PARIS 5 · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2019 to 2019
$1.5M
British Heart Foundation RG/16/11/32334Medical Research Council K013351Medical Research Council MR/R024227/1Medical Research Council MR/S011676/1Medical Research Council R024227Medical Research Council S011676NIA NIH HHS R01 AG056477NIA NIH HHS RF1 AG062553Wellcome TrustWellcome Trust 221854/Z/20/Z
6 · The paper itself

Abstract

backgroundSleep duration has been shown to be associated with individual chronic diseases but its association with multimorbidity, common in older adults, remains poorly understood. We examined whether sleep duration is associated with incidence of a first chronic disease, subsequent multimorbidity and mortality using data spanning 25 years. METHODS AND

findingsData were drawn from the prospective Whitehall II cohort study, established in 1985 on 10,308 persons employed in the London offices of the British civil service. Self-reported sleep duration was measured 6 times between 1985 and 2016, and data on sleep duration was extracted at age 50 (mean age (standard deviation) = 50.6 (2.6)), 60 (60.3 (2.2)), and 70 (69.2 (1.9)). Incidence of multimorbidity was defined as having 2 or more of 13 chronic diseases, follow-up up to March 2019. Cox regression, separate analyses at each age, was used to examine associations of sleep duration at age 50, 60, and 70 with incident multimorbidity. Multistate models were used to examine the association of sleep duration at age 50 with onset of a first chronic disease, progression to incident multimorbidity, and death. Analyses were adjusted for sociodemographic, behavioral, and health-related factors. A total of 7,864 (32.5% women) participants free of multimorbidity had data on sleep duration at age 50; 544 (6.9%) reported sleeping ≤5 hours, 2,562 (32.6%) 6 hours, 3,589 (45.6%) 7 hours, 1,092 (13.9%) 8 hours, and 77 (1.0%) ≥9 hours. Compared to 7-hour sleep, sleep duration ≤5 hours was associated with higher multimorbidity risk (hazard ratio: 1.30, 95% confidence interval = 1.12 to 1.50; p < 0.001). This was also the case for short sleep duration at age 60 (1.32, 1.13 to 1.55; p < 0.001) and 70 (1.40, 1.16 to 1.68; p < 0.001). Sleep duration ≥9 hours at age 60 (1.54, 1.15 to 2.06; p = 0.003) and 70 (1.51, 1.10 to 2.08; p = 0.01) but not 50 (1.39, 0.98 to 1.96; p = 0.07) was associated with incident multimorbidity. Among 7,217 participants free of chronic disease at age 50 (mean follow-up = 25.2 years), 4,446 developed a first chronic disease, 2,297 progressed to multimorbidity, and 787 subsequently died. Compared to 7-hour sleep, sleeping ≤5 hours at age 50 was associated with an increased risk of a first chronic disease (1.20, 1.06 to 1.35; p = 0.003) and, among those who developed a first disease, with subsequent multimorbidity (1.21, 1.03 to 1.42; p = 0.02). Sleep duration ≥9 hours was not associated with these transitions. No association was found between sleep duration and mortality among those with existing chronic diseases. The study limitations include the small number of cases in the long sleep category, not allowing conclusions to be drawn for this category, the self-reported nature of sleep data, the potential for reverse causality that could arise from undiagnosed conditions at sleep measures, and the small proportion of non-white participants, limiting generalization of findings.

conclusionsIn this study, we observed short sleep duration to be associated with risk of chronic disease and subsequent multimorbidity but not with progression to death. There was no robust evidence of an increased risk of chronic disease among those with long sleep duration at age 50. Our findings suggest an association between short sleep duration and multimorbidity.

Indexed as

MultimorbiditySleep Wake DisordersAgedCohort StudiesFemaleFollow-Up StudiesHumansLondonMaleMiddle AgedProspective StudiesRisk FactorsSleep

Identifiers

PMID36256607
PMCPMC9578599
OpenAlexW4306732432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.